Clinical Trial Update: A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021) [Phase 1]

View source ↗

Summary

Phase 1 study of Belzutifan (MK-6482) in participants with renal impairment (MK-6482-021) has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Renal Impairment

Drugs mentioned

• Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: End Stage Renal Disease, Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2025-04-06